176 related articles for article (PubMed ID: 35439334)
1. Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
Bruijnen CP; Koldenhof JJ; Verheijden RJ; van den Bos F; Emmelot-Vonk MH; Witteveen PO; Suijkerbuijk KPM
Cancer; 2022 Jul; 128(14):2746-2752. PubMed ID: 35439334
[TBL] [Abstract][Full Text] [Related]
2. Association between PD-1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients.
Li J; Zhang X; Zhou S; Zhou Y; Liu X
Cancer Med; 2023 Apr; 12(8):9272-9281. PubMed ID: 36727563
[TBL] [Abstract][Full Text] [Related]
3. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
Olsson Ladjevardi C; Koliadi A; Rydén V; Inan El-Naggar A; Digkas E; Valachis A; Ullenhag GJ
Cancer Med; 2023 Jun; 12(12):13217-13224. PubMed ID: 37132258
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
5. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients.
Tong J; Kartolo A; Yeung C; Hopman W; Baetz T
Curr Oncol; 2022 Oct; 29(10):7953-7963. PubMed ID: 36290906
[TBL] [Abstract][Full Text] [Related]
7. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L; Dalle S; Dereure O; Trabelsi S; Dalac S; Legoupil D; Montaudié H; Arnault JP; De Quatrebarbes J; Saiag P; Brunet-Possenti F; Lesimple T; Maubec E; Aubin F; Granel-Brocard F; Grob JJ; Stoebner PE; Allayous C; Oriano B; Dutriaux C; Mortier L; Lebbe C
Ann Rheum Dis; 2022 Oct; 81(10):1445-1452. PubMed ID: 35788496
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
Balaji A; Zhang J; Wills B; Marrone KA; Elmariah H; Yarchoan M; Zimmerman JW; Hajjir K; Venkatraman D; Armstrong DK; Laheru DA; Mehra R; Ho WJ; Reuss JE; Heng J; Vellanki P; Donehower RC; Holdhoff M; Naidoo J
J Oncol Pract; 2019 Sep; 15(9):e825-e834. PubMed ID: 31386608
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
11. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C; Hoefsmit EP; Fangmeier T; Kramer N; Kabakci C; Vera González J; Versluis JM; Compter A; Harrer T; Mijočević H; Schubert S; Hundsberger T; Menzies AM; Scolyer RA; Long GV; French LE; Blank CU; Heinzerling LM
Cancer Immunol Immunother; 2023 Nov; 72(11):3475-3489. PubMed ID: 37606856
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
[TBL] [Abstract][Full Text] [Related]
16. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
17. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
18. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience.
Archibald WJ; Victor AI; Strawderman MS; Maggiore RJ
J Geriatr Oncol; 2020 Apr; 11(3):496-502. PubMed ID: 31303463
[TBL] [Abstract][Full Text] [Related]
20. Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality.
Yan C; Huang M; Swetlik C; Toljan K; Mahadeen AZ; Bena J; Kunchok A; Funchain P; McGinley M
Eur J Neurol; 2023 Oct; 30(10):3221-3227. PubMed ID: 37350150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
